Related Experiment Video
Updated: May 11, 2026
05:51
Characterization of a Novel Human Organotypic Retinal Culture Technique
Published on: June 9, 2021
[Incretin therapy and diabetic retinopathy]
1Interní klinika 2. lékarské fakulty UKa FN Motol Praha. Interna@fnmotol.cz
Vnitrni Lekarstvi
|May 30, 2013
Summary
Incretin-based therapies offer an effective, safe treatment for type 2 diabetes, with benefits like low hypoglycemia risk and positive weight effects. Emerging research suggests incretin therapy may also favorably impact diabetic retinopathy.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Context:
- Type 2 diabetes mellitus (T2DM) management requires therapies with improved efficacy, safety, and metabolic profiles.
- Incretin-based therapies represent a novel class of antidiabetic medications targeting the incretin system.
Purpose:
- To review the efficacy, safety, and broader metabolic and cardiovascular benefits of incretin-based therapies in T2DM.
- To explore the emerging evidence for incretin therapy's impact on diabetic retinopathy pathophysiology.
Summary:
- Incretin-based therapies are efficient and safe for T2DM, characterized by a low risk of hypoglycemia and beneficial effects on body weight.
- Published analyses consistently demonstrate a positive influence on cardiovascular risk factors.
- Preliminary studies in animal models indicate a favorable effect of incretin therapy on the pathophysiology of diabetic retinopathy.
Impact:
- Provides a comprehensive overview of incretin therapy's established benefits in T2DM.
- Highlights the potential of incretin therapy to mitigate cardiovascular risk.
- Suggests a promising new therapeutic avenue for managing diabetic retinopathy complications.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...